Project Grant R03HL187211
Award Date 8/1/26
Completion Date 7/31/28
Dollars Obligated $238K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Indianapolis, IN 46202, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded Brown University $100,228 on December 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the role of chitinase 3-like-1 in pulmonary arterial hypertension pathogenesis. The project grant funds research into how the protein CHI3L1 contributes to immune and metabolic dysfunction underlying vascular remodeling in PAH, with particular focus on macrophage metabolism and pro-remodeling effects. The research...
- The National Heart, Lung, and Blood Institute awarded $1.775 million to Boston Children's Hospital on September 1, 2026, to investigate pericyte-to-smooth-muscle-cell transitions in pulmonary arterial hypertension, under the Cardiovascular Diseases Research program (CFDA 93.837). The research addresses excessive vascular remodeling in pulmonary arterial hypertension by examining how pericytes—specialized mural cells that maintain capillary stability—transition into smooth muscle-like cells under...
- The National Heart, Lung, and Blood Institute awarded Brigham & Women's Hospital Inc. $1,540,621 on September 15, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate endothelial inflammation, C-terminal SRC kinase dysregulation, and fibrosis in early pulmonary arterial hypertension. The award funds research into molecular mechanisms regulating fibroproliferative pulmonary vascular remodeling in early PAH, with particular focus on patients with inflammatory...
- The National Heart, Lung, and Blood Institute awarded the University of Maryland, Baltimore $775,687 under Project Grant R01HL183332 on August 10, 2026, to support research on molecular drivers of pulmonary vascular remodeling in pulmonary hypertension with heart failure and preserved ejection fraction (PH-HFPEF). The research investigates beta-2 microglobulin (B2M) as a therapeutic target in PH-HFPEF. The project builds on findings that PH-HFPEF patients display elevated circulating B2M...
- The National Heart, Lung, and Blood Institute awarded the University of Washington $264,750 on July 1, 2026, for a Project Grant (R03HL178552) under the Cardiovascular Diseases Research program (CFDA 93.837) to identify pathogenic somatic mutations in pulmonary arterial hypertension. The award funds research to determine whether somatic (acquired) mutations in disease-causing pathways contribute to PAH pathogenesis. The work proceeds through two approaches: analyzing cell-free DNA in circulating...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Vanderbilt University Medical Center $341,280 on September 19, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to support a five-year mentored career development project investigating apoptosis resistance mechanisms in pulmonary arterial smooth muscle cells. Dr. Niedermeyer, under mentorship from Dr. Larissa Shimoda and Dr. Mahendra Damarla, will conduct hands-on laboratory research, complete...
- The National Heart, Lung, and Blood Institute awarded the University of California, Los Angeles $723,400 on August 6, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate asporin as a dual-pathway therapeutic target and biomarker for pulmonary arterial hypertension. The project, designated R01HL183171, addresses pulmonary arterial hypertension (PAH), a progressive and fatal vascular disease marked by pulmonary vascular remodeling and right ventricular failure,...
- The National Heart, Lung, and Blood Institute, a component of the Department of Health and Human Services National Institutes of Health, awarded $792,498 to the Trustees of Indiana University (doing business as Indiana University Indianapolis) on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate gene-environment interactions in congenital heart disease, specifically the role of maternal obesity in offspring cardiac development. The research...
- The National Heart, Lung, and Blood Institute awarded the Trustees of Indiana University $516,592 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct integrative genomic analysis and develop high-dimensional risk prediction models for congenital heart defects using random field methods. The research leverages existing biospecimens and data from the National Birth Defect Prevention Studies, the Pediatric Cardiac Genomics Consortium, and the Trans-Omics for...
- The National Heart, Lung, and Blood Institute awarded The Johns Hopkins University $776,005 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 1, 2026, to fund research on beta-hydroxybutyrate–mediated endothelial cell and skeletal muscle dysfunction in pulmonary arterial hypertension. The project, R01HL184469, runs through May 31, 2031, with work performed in Baltimore, Maryland. The research addresses the mechanisms linking mitochondrial dysfunction in lung...